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Abstract
Stress is the most commonly reported precipitating factor for seizures in patients with epilepsy. Despite compelling
anecdotal evidence for stress-induced seizures, animal models of the phenomena are sparse and possible mechanisms are
unclear. Here, we tested the hypothesis that increased levels of the stress-associated hormone corticosterone (CORT) would
increase epileptiform activity and spontaneous seizure frequency in mice rendered epileptic following pilocarpine-induced
status epilepticus. We monitored video-EEG activity in pilocarpine-treated mice 24/7 for a period of four or more weeks,
during which animals were serially treated with CORT or vehicle. CORT increased the frequency and duration of epileptiform
events within the first 24 hours of treatment, and this effect persisted for up to two weeks following termination of CORT
injections. Interestingly, vehicle injection produced a transient spike in CORT levels – presumably due to the stress of
injection – and a modest but significant increase in epileptiform activity. Neither CORT nor vehicle treatment significantly
altered seizure frequency; although a small subset of animals did appear responsive. Taken together, our findings indicate
that treatment of epileptic animals with exogenous CORT designed to mimic chronic stress can induce a persistent increase
in interictal epileptiform activity.
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Introduction
Stress is widely recognized as a precipitating factor for seizures
in many patients with epilepsy [1–4]. Despite a clear correlation
between stress and seizures such that many patients are able to
predict their own seizures with great accuracy [5–7], whether a
causal relationship between stress and epilepsy exists is not known.
Indeed, changes in the brain preceding a seizure might increase
patient perceptions of stress and anxiety rather than the converse.
Alternatively, factors related to stress, such as sleep loss, rather
than stress per se may account for the correlation. Nonetheless,
understanding the relationship between stress and seizures is
important. Chronic stress can lead to lasting changes in brain
structure and function [8–11], providing a possible mechanism by
which stress might impact epilepsy. For example, in the
hippocampus – a brain region implicated in temporal lobe
epilepsy – stress alters dentate granule cell proliferation [12,13]
and regulates dendritic and synaptic plasticity [14–16]. Therefore,
it is conceivable that stressful events could increase the likelihood
that at-risk individuals will develop epilepsy, or worsen the course
of the disease in patients with pre-existing epilepsy. Identifying
such ‘‘disease-modifying’’ effects of stress on epilepsy could be
extremely important for clinical management of the disorder.
Stress activates the hypothalamic–pituitary–adrenal (HPA) axis,
leading to the release of a variety of neuropeptides and hormones
[17]. Glucocorticoids – corticosterone (CORT) in rodents and
cortisol in humans – are prominent among these. CORT exerts its
effects through high-affinity mineralocorticoid receptors and
comparatively lower affinity glucocorticoid receptors. Both recep-
tors act by binding DNA response elements to alter gene
expression, and are thus capable of producing relatively slow
developing but long-lasting changes in transcription. In addition,
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glucocorticoids can also act through non-genomic mechanisms,
leading to more rapid changes in behavior and physiology [18,19].
Both receptor types are expressed at high levels in cortex and
hippocampus [20–24] and act to regulate the excitability of
cortical and hippocampal neurons [25].
Although the mechanisms underlying epileptogenesis are still
being elucidated, it is clear that many patients’ seizures originate
from discrete brain regions. These brain regions often exhibit
damage from injury (e.g. hypoxia, status epilepticus), tumors or
developmental defects (e.g. heterotopias), and are commonly
found in the cortex or temporal lobe. Surgical removal of these
damaged regions is highly effective at controlling seizures [26],
providing compelling evidence that these regions originate the
seizures. Evidence for disease-causing brain lesions in patients with
epilepsy, however, fails to explain the paroxysmal nature of the
disorder. To restate the question, why should epileptic foci, which
are always present, only occasionally provoke seizures? The
implication is that most of the time, the balance between excitation
and inhibition in the brain is adequately maintained such that
despite the presence of an epileptic focus, seizures do not occur.
Changes in factors which can alter excitation and inhibition in
brain presumably upset this balance sporadically, provoking
seizures. The present study explores whether CORT could be
one of those factors.
To determine whether increasing CORT levels in animals with
pre-existing epilepsy would provoke seizures, we treated epileptic
mice with exogenous CORT while monitoring ictal and interictal
EEG activity. Animals were rendered epileptic using the
pilocarpine-status epilepticus model of epilepsy.
Results
In the present study, epileptic animals were implanted with
wireless EEG transmitters and were monitored by video-EEG 24/
7 to determine the impact of corticosterone (CORT) treatment on
epileptic activity. EEG records were screened to identify epilep-
tiform events and overt seizures. EEG seizures were characterized
by the sudden onset of high amplitude activity, with evolving
frequency and amplitude over the course of the event, and abrupt
termination (Fig. 1, B). Seizures were frequently, but not always,
associated with behavioral symptoms that included mouth
automations, myoclonic jerking, forelimb clonus, rearing and
falling (up to class V, Racine scale) [27]. By contrast, epileptiform
activity was defined here as periods of repetitive spiking or bursting
with a frequency of 3–120/minute and lasting for at least 30
seconds (Fig. 1, C). This activity was similar to patterns described
in other models of epilepsy [28], and tended to wax and wane over
time. During epileptiform events, animals typically exhibited little
or no movement, and did not engage in normal behaviors
(exploring the cage, eating, grooming) although they remained
upright. Cessation of epileptiform activity corresponded with a
return to normal behavior.
Corticosterone increases epileptiform activity
To determine whether CORT altered the incidence of
epileptiform activity in epileptic animals, epileptiform events were
quantified during the 24-hour periods immediately preceding and
following the first vehicle and CORT injections (Fig. 2, A, arrows).
CORT significantly increased the number (p,0.032) and total
duration (p,0.047) of epileptiform EEG events in epileptic
animals relative to baseline EEG activity in the preceding 24 hours
(Fig. 2, B–C). Vehicle injection also significantly increased the
duration (p = 0.049) of epileptiform events relative to baseline
(Fig. 2, C). The response to vehicle treatment, however, was
significantly less than that following CORT treatment (p = 0.017
for event number; p = 0.022 for duration). Epileptiform activity
was absent from control animals under all conditions.
Effects of corticosterone treatment on seizure frequency
To determine whether CORT treatment altered seizure
frequency or duration, seizure rates during vehicle treatment
and CORT treatment periods were compared to rates during all
other periods. No significant changes in seizure frequency (Fig. 2,
D; p = 0.447) or mean seizure duration (Fig. 2, E; p = 0.294,
Kruskal-Wallis One Way ANOVA on Ranks) were found among
the different treatments. Although overall rates were not
significantly different for the entire group of animals, one animal
exhibited seizures only during CORT treatment (Fig. 3, E) and
two animals appeared to respond to both vehicle and CORT
treatment with increased seizures (Fig. 3, A & C). Indeed, the
animal shown in C exhibited a dramatic increase in seizures
during CORT treatment on the first day and died on the second
day after having 45 seizures. Whether the apparent responses to
CORT among a subset of animals reflect actual responses, or just
coincidence, however, remains uncertain. None of the control
animals showed any baseline seizures nor did they exhibit any
seizures during vehicle or CORT injections (data not shown).
Measurement of corticosterone levels in plasma
In the present study, animals were treated sequentially with
vehicle for one week, followed by a 1–2 week recovery and then
CORT for one week. To confirm that this treatment paradigm
was effective at raising CORT above baseline levels, four control
mice were run through the protocol. On the first day of vehicle or
CORT treatment, CORT levels were measured just prior to
injection, as well as thirty minutes and two hours after injection.
Thirty minutes after vehicle and CORT injections, CORT levels
were increased 10–12 fold relative to the respective baseline
(p,0.001; two-way ANOVA on ranked data with treatment and
time after injection as factors; Holm-Sidak post-test). The increase
following vehicle injection likely reflects endogenous CORT due
Figure 1. EEG recordings from epileptic animals. A: Baseline EEG
activity. B: A typical seizure event in an epileptic animal. This seizure
was associated with behavioral rearing and loss of postural control
(falling). C: An example of epileptiform activity recorded from an
epileptic animal. The EEG segments shown below B and C are
expansions of the periods marked by the solid bars. Animals were
typically motionless or exhibited myoclonic jerks during epileptiform
events.
doi:10.1371/journal.pone.0046044.g001
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to handling stress [29]. Two hours after injections, CORT levels
began to decline in vehicle treated animals (2 hrs vs. 30 m,
p = 0.009), though levels were still significantly above baseline
(2 hrs vs. baseline, p = 0.010). In CORT treated animals, CORT
levels increased dramatically between thirty minutes and two
hours (p,0.001). At two hours, CORT levels in CORT injected
animals were significantly higher than vehicle injected animals at
the same time point (p,0.001). Plasma CORT levels for these
time points are shown in figure 4. Our results indicate that vehicle
injection can lead to a stress induced increase in CORT, however,
the elevation of CORT is transient and of lower amplitude than
levels produced by CORT injection.
CORT effects persist beyond the termination of
treatment
Given the transient but significant increase in CORT from
vehicle injection alone, and increased duration of epileptiform
activity in vehicle injected mice (Fig. 2, C), we queried whether
epileptic animals might respond differently if the protocol was
reversed and ‘‘naı¨ve’’ epileptic animals were given CORT in the
first injection.
Despite the reversed protocol, CORT treatment did not
significantly alter seizure frequency (Fig. 5, D; p = 0.273) or
duration (Fig. 5, E; p = 0.175), suggesting that prior vehicle
injection stress did not blunt the response to exogenous CORT.
Seizure patterns within animals also failed to exhibit any
compelling correlations between treatment periods and seizure
incidence (Fig. 6). Consistent with the findings from animals
treated with vehicle first, however, CORT still produced a
dramatic increase in the number (p,0.001) and total duration
(p = 0.002) of epileptiform events relative to the preceding baseline
period (Fig. 5, B–C).
The reversed protocol revealed one additional surprising
finding. Specifically, once epileptic animals had been exposed to
CORT, the number and duration of epileptiform events never
recovered to pre-CORT baseline levels. Relative to the first
baseline, both the number (p = 0.003) and duration (p = 0.003) of
epileptiform events was increased during the second (post-CORT)
baseline. Similar increases were observed during vehicle treatment
relative to the first baseline (Fig. 5, B–C). The baseline period
following CORT treatment ranged from 12–14 days, and
epileptiform events were quantified during the last 24 hours of
this period, so this increase was evident despite an almost two-
week recovery period since the last CORT injection. Moreover,
this would not appear to be due to epilepsy progression in these
animals unrelated to CORT treatment, because animals in the
first experiment did not exhibit an increase in epileptiform activity
during their second baseline monitoring period (Fig. 2, B–C),
despite being at equivalent time points after status epilepticus
(vehicle first group, 3.461.9 months after SE at beginning of
protocol; CORT first group, 3.662.6 months; p = 0.939, t-test). A
post-hoc comparison for the 2nd baseline period between the
vehicle-first group and the CORT-first group revealed that the
latter was significantly greater than the former for both the
number (p = 0.004, t-test) and duration (p = 0.003, t-test) of
epileptiform events. These findings strongly suggest that exposure
to exogenous CORT, and not time after status epilepticus, is
responsible for the persistent increase in epileptiform activity.
Figure 2. Schematic and graphs illustrating the experimental approach (A) and results (B–E) for animals treated with vehicle
followed by CORT. A: Experimental protocol for the vehicle-first treatment regimen. Video-EEG was monitored continuously throughout the entire
regimen, with each period corresponding to 1–2 weeks. Twenty-four hour EEG segments quantified for epileptiform activity are denoted by arrows.
The color of each part of the timeline corresponds to the bar color in the graphs shown below. B: CORT treatment significantly increased the number
of epileptiform events relative to all other periods. C: CORT treatment significantly increased the total duration of epileptiform events relative to all
other periods. Vehicle treatment also significantly increased the duration of events relative to the 1st baseline period. D: No significant effects of
vehicle or CORT treatment on seizure frequency were found. E: Mean seizure duration was statistically equivalent among treatment groups and
baseline periods. Bar graphs show means 6 SEM. *, p,0.05.
doi:10.1371/journal.pone.0046044.g002
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Seizure activity does not exhibit diurnal rhythms
Corticosteroid levels show diurnal variations in rodents; levels
are low in the morning and peak in the evening. To explore
whether these variations in endogenous CORT levels might
impact excitability, seizure activity during the first week of
recording (before any treatments) was binned into four 6-hour
segments. For the six animals that had seizures during the baseline
period, no significant variations in seizure frequency among the
four periods were found (6AM-Noon, 0.2060.14 seizures/6 hr
period; Noon-6PM, 0.3960.16; 6PM-Midnight, 0.4460.23;
Midnight-6AM, 0.2560.13; one-way ANOVA, p = 0.711), con-
sistent with recent work [30]. Since animals did not exhibit
epileptiform activity (as defined in the methods) during the first
week of recording, diurnal variations were not examined for this
parameter.
Discussion
Stress is the most commonly reported seizure precipitant in
patients with epilepsy [1–4]. A mechanistic link between stress and
seizures, however, is lacking. Here, we sought to determine
whether exogenous CORT treatment at levels designed to mimic
chronic stress would provoke seizures in epileptic animals. CORT
is increased under stressful conditions [31] and since CORT can
enhance neuronal excitability [25], it is an obvious candidate for
Figure 3. Individual seizure timelines of epileptic animals receiving vehicle first. Periods of vehicle and CORT treatment are highlighted in
blue and red, respectively, while baseline periods are left white. Bars denote the number of seizures on a given day. One animal exhibited seizures
only during CORT treatment (E), while 2 animals (A & C) exhibited seizures primarily during periods of vehicle and CORT treatment. The remaining
four animals showed no compelling correlation between seizure incidence and treatment, and overall there was no significant effect of treatment on
seizure frequency.
doi:10.1371/journal.pone.0046044.g003
Figure 4. Plasma corticosterone levels measured in a group of
non-epileptic (control) mice. CORT levels were determined
following vehicle (blue) and CORT (red) injection. Levels were
measured just prior to injection (baseline), thirty minutes (30 m) after
injection and two hours after injection. At 30 minutes, both vehicle
and CORT injection elevated CORT levels significantly. At 120 minutes,
CORT levels began to come down in the case of the vehicle injection,
though still significantly higher than baseline levels. Following CORT
injection, levels continued to increase beyond 30 minutes.ˆˆ ,ˆ p,0.001
vs. baseline for both vehicle and CORT; ***, p,0.001 vs. all other
groups and time points.
doi:10.1371/journal.pone.0046044.g004
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Figure 5. Schematic and graphs illustrating the experimental approach (A) and results (B–E) for animals treated with CORT
followed by vehicle. A: Experimental protocol for the CORT-first treatment regimen. Video-EEG was monitored continuously throughout the entire
regimen, with each period corresponding to 1–2 weeks. Twenty-four hour EEG segments quantified for epileptiform activity are denoted by arrows.
The color of each part of the timeline corresponds to the bar color in the graphs shown below. B: CORT treatment significantly increased the number
of epileptiform events relative to the preceding baseline period (1st base). The number of epileptiform events was also increased during subsequent
periods (2nd baseline, vehicle) relative to the first baseline. C: CORT treatment significantly increased the total duration of epileptiform events relative
to the preceding baseline period. The total duration of epileptiform events was also increased during subsequent periods relative to the first baseline.
**, p,0.01 vs. 1st baseline; ***, p,0.001 vs. 1st baseline. D: No significant effects of vehicle or CORT treatment on seizure frequency were found. E:
Mean seizure duration was statistically equivalent among treatment groups and baseline periods. Bar graphs show means 6 SEM.
doi:10.1371/journal.pone.0046044.g005
Figure 6. Individual seizure timelines of epileptic animals receiving CORT first. Periods of vehicle and CORT treatment are highlighted in
blue and red, respectively, while baseline periods are left white. Bars denote the number of seizures on a given day. No striking correlations between
treatment and seizure incidence were observed for these animals.
doi:10.1371/journal.pone.0046044.g006
Effects of Corticosterone in Epileptic Mice
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modulating seizure frequency in patients with epilepsy. Interest-
ingly, while we did not find a significant increase in overt seizures
following CORT treatment, CORT produced a robust and long-
lasting increase in epileptiform activity. Epileptiform events were
characterized by repetitive spiking and/or bursting in the cortical
EEG. These events could last for minutes to hours during which
the animals were largely immobile. The increase in epileptiform
events persisted for at least two weeks after the last CORT
injection, indicating that CORT can have long-lasting effects on
excitability in epilepsy. Vehicle injection also increased the
duration of epileptiform events, although effects were modest
relative to CORT and did not persist. Perhaps not coincidentally,
vehicle injection produced a transient increase in plasma CORT
levels. It is conceivable that this endogenous CORT, induced by
injection stress, accounts for the increase in epileptiform activity.
Importantly, none of the control, non-epileptic animals exhibited
epileptiform activity or seizures in their EEG following vehicle or
CORT administration. Taken together, our results support the
conclusion that CORT can induce a long-lasting increase in
epileptiform activity that is specific to epileptic animals. These
findings further suggest that CORT could have disease-modifying
effects in epilepsy.
Relevance to prior studies
Numerous studies have demonstrated that CORT treatment
can alter neuronal activity in normal animals. For example,
CORT can increase the frequency of miniature excitatory
postsynaptic currents [32], enhance L-type calcium currents [33]
and paradoxically, can both facilitate and impair the induction of
long-term potentiation (LTP), depending on the timing of
treatments and presence of other neuromodulators [34–36]. The
effects of CORT on LTP highlight the complex dynamics
underlying CORT responses. Indeed, the impact of CORT can
vary among brain regions and neuronal subtypes. It can act
synergistically or antagonistically with other hormones and an
animal’s response to CORT can be influenced by its life history
(e.g. perinatal stress exposure). Notably, all of these studies were
conducted in normal animals and CORT effects on the epileptic
brain may differ significantly.
The existing literature provides some additional insight into the
effects of CORT on the epileptic brain. Cortisone treatment of
photosensitive baboons has been shown to increase seizure activity
[37] and corticosterone treatment of WAG/Rij rats, used to model
absence epilepsy, increased the incidence of spike-wave discharges
[38]. Stress also increased spike-wave discharges in these animals
[39], a finding also reminiscent of the present work. For these
latter studies, however, we note that the mechanisms underlying
absence epilepsy are thought to be very different than those
underlying the temporal lobe epilepsy model used here, so the
comparison is made cautiously. Stressor exposure has been shown
to provoke seizures in a number of epilepsy models [40,41],
although whether this effect is mediated by CORT is not known.
A greater number of studies have demonstrated pro-convulsant
effects of CORT under acute conditions in normal animals,
although these findings again reflect the actions of CORT on the
normal, not epileptic, brain. Nonetheless, it has been demonstrat-
ed that CORT can act synergistically with the convulsant drug
kainic acid. Specifically, CORT decreases the dose of kainic acid
required to produce seizures in mice [42], and increases the
number of brain slices exhibiting multiple population spikes in
response to Schaeffer collateral stimulation, a measure of
epileptogenesis [43]. In the kindling model of epilepsy, CORT
has been found to reduce the number of stimulations required to
evoke seizures, significantly accelerating kindling epileptogenesis
[44–47]. Whether CORT exacerbates or mitigates neuronal
injury in seizure models is controversial, with studies demonstrat-
ing both protective [48] and neurotoxic effects [49–51]. Differ-
ences in treatments and their timing, species and models are likely
important, and again highlight the complexity of this system [52].
In general, however, the majority of studies support the idea that
CORT can act in a pro-convulsant, and possibly pro-epileptogenic
fashion.
Seizure frequency in epileptic animals following CORT
treatment
Although CORT clearly increased epileptiform activity in
epileptic animals, no change in seizure frequency was found.
Nevertheless, we interpret this negative result somewhat cautious-
ly. Specifically, although there was no overall effect on seizure
frequency, three of the ten animals (Fig. 3, A, C & E) exhibited a
striking correspondence between treatments and seizure incidence,
with seizures occurring primarily during periods of vehicle or
CORT injection, and with the latter being associated with the
greater number of seizures. Since vehicle injection transiently
increased CORT levels, CORT could be provoking seizures under
both treatment conditions. It is possible that not all epileptic
animals will respond to CORT with increased seizures, so the
apparent lack of response in some animals does not preclude the
possibility of a response in others. Indeed, studies of human
epilepsy clearly indicate that some patients report stress-induced
seizures, and some do not [4]. It is reasonable to think that animals
might show similar variability, and although attempts were made
to keep experimental animals as homogenous as possible, the
pilocarpine model of epilepsy can produce very heterogeneous
patterns of cell loss and plasticity [53]. No overt differences in
gross brain pathology were observed between ‘‘responding’’ and
‘‘non-responding’’ animals in the present study (data not shown),
but the possibility that more subtle differences are important
cannot be excluded.
A second feature that might make it difficult to detect an effect
of CORT on seizure frequency is the tendency for seizures to
occur in clusters. Seizure clustering has been observed previously
[54–57], and may reflect excitatory changes in the pre-ictal period
that make seizures more likely, followed by a refractory period
during which seizures are inhibited. In the present study, group
assignments were made randomly, and no attempt was made to
coordinate seizure clusters with treatments to avoid biasing the
results; however, the timing of CORT treatments relative to the
stage of this natural cycle could exert an important modulatory
effect on the CORT response. This interesting question could be
addressed with even longer recording periods and a systematic
timing of CORT injections, although such experiments will
require improved technologies, as transmitter battery life is only 8–
10 weeks. Alternatively, other animal models of epilepsy with more
constant daily seizure rates might be superior for assessing the
impact of CORT on epilepsy.
Variability in endogenous CORT levels and HPA axis function
might also impact the response of epileptic mice to exogenous
CORT. Seizures increase CORT levels acutely [58,59], and
epileptic animals [60,61] and humans [62] exhibit hyperactive
HPA axes. Complex interactions between exogenously applied
CORT and endogenous CORT rhythms could make it more
difficult to identify a clear effect of treatment. Disrupted HPA axis
function in epileptic animals could also make it more difficult to
identify any effects of endogenous CORT rhythms on seizure
occurrence. We examined seizure occurrence during the baseline
monitoring period – prior to any treatments the might alter the
diurnal CORT rhythm – and did not observe any variation in
Effects of Corticosterone in Epileptic Mice
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seizure incidence throughout the day. Similar results have been
reported previously [30], however, the extent to which epileptic
animals follow the diurnal CORT rhythms seen in healthy
controls is not clear, so negative results should be interpreted with
this caveat in mind. Future studies using methods to suppress the
effects of endogenous CORT, such as adrenalectomy, glucocor-
ticoid antagonists and/or genetic strategies [63], might prove
superior at exploring the possible role of endogenous CORT in
seizure occurrence.
Significance of increased epileptiform activity
The major finding of the present study is that CORT treatment
increases epileptiform activity in animals with pre-existing
epilepsy, and that this increase persists for at least two weeks after
the last CORT injection. Epileptiform activity is associated with
greater cognitive disruption and poorer prognosis in patients with
epilepsy [64–66], so the changes observed here are likely harmful.
Furthermore, this finding is significant as it suggests that CORT
may exert disease-modifying effects on the epileptic brain. In
contrast to agents which only affect the disease phenotype when
present, a disease-modifying agent could produce a lasting, and
potentially irreversible, change in disease severity or progression.
Whether the changes observed here persist beyond two weeks is
not known, but the present findings suggest that levels of CORT
similar to those observed during chronic stress might produce a
lasting increase in abnormal EEG activity in patients with epilepsy.
Materials and Methods
Pilocarpine treatment
All procedures involving animals were approved by the
Institutional Animal Care and Use Committee of the Cincinnati
Children’s Hospital Research Foundation and conform to
National Institute of Health guidelines for the care and use of
animals. Four to six-week-old male C57BL/6 mice (Charles River
Laboratories International, Inc., Wilmington, MA) were housed
on a 14/10 (light/dark) cycle with access to food and water ad
libitum. Between 8–10 weeks of age, the animals were pre-treated
with a subcutaneous (s.c.) injection of methyl scopolamine nitrate
(1 mg/kg) followed 15 minutes later by 420 mg/kg pilocarpine s.c.
All pilocarpine treatments were done between 10:00 AM and
12:00 PM to limit diurnal variation. Mice were observed to
determine the onset of status epilepticus (SE), defined behaviorally
by continuous tonic/clonic convulsions or shorter tonic/clonic
convulsions without recovery between episodes. Three hours after
the onset of SE, mice received two doses of diazepam (10 mg/kg;
Sigma-Aldrich, St. Louis, MO) at 15 min intervals. Mice were
housed in a 32uC incubator for the next 48 hours and given warm
(30–33uC) Ringers s.c. (3–5 times) to maintain pretreatment body
weight and improve recovery.
24-7 Video-EEG monitoring
Eleven pilocarpine-treated epileptic animals were implanted
with wireless transmitters for continuous EEG monitoring [67–
70]. Animals were implanted 1–12 months after pilocarpine-status
epilepticus. In addition, five untreated control mice were also
implanted. For transmitter implantation, animals were anesthe-
tized with 3.5% isoflurane in oxygen and then maintained at 0.7–
1.2% isoflurane throughout the procedure. Transmitter leads
(TA11ETA-F10, Data Sciences International [DSI], St. Paul, MN)
were placed into two 0.9 mm diameter holes positioned over the
left and right cortical hemispheres (1–1.2 mm anterior to the
lambda suture and 1.5 mm lateral to the midline). Care was taken
not to perforate the dura so that skull encapsulation remained
intact. Anchor screws (shaft diameter 1.16 mm, length 1.6 mm)
were placed <2 mm anterior to the transmitter leads and both
leads and screws were secured in place with dental cement. The
transmitter was inserted into a subcutaneous pocket posterior to
the neck. Following placement of the leads and transmitter, the
incision was closed. The ability to close the wound completely is a
significant advantage of wireless recording, as it greatly reduces
infection risk and facilitates chronic recording. Mice were given
48 hours to recover before EEG recordings were begun and at
least one week to recover before vehicle or CORT treatments
were begun.
EEG and video recordings were performed in an isolated, sterile
room equipped with the DSI wireless telemetry system running
DATAQUEST A.R.T. (version 4.2) acquisition software (DSI).
The room has the same light/dark cycle as the vivarium. The
EEG signal was digitized at 250 Hz. A total of 9320 hours of
video-EEG data was collected from eleven epileptic animals and
2906 hours was collected from five control animals. EEG data was
analyzed by an experimenter unaware of treatment using Neuro-
score software (version 2.0, DSI). Seizures were defined as a
sudden onset of high amplitude (.26 background) activity with
signal progression (a change in amplitude and frequency over the
course of the event) and a duration greater than ten seconds (Fig. 1.
B). Animals were also scored for periods of epileptiform activity
that could not be strictly defined as seizures. Epileptiform activity
was defined as periods of rhythmic spiking or bursting that lasted a
minimum of 30 seconds. Activity included runs of spikes,
polyspikes and sharp waves with a frequency of 0.5–2 Hz. In
addition, 1–5 second bursts of paroxysmal high frequency (50–
100 Hz) activity occurring every 5–20 seconds (Fig. 1, C) were
scored when more than four bursts in a row occurred. The
duration and frequency of epileptiform events was quantified for
each animal in the 24 hour periods immediately preceding and
following vehicle or CORT administration.
Corticosterone treatment regimen
Epileptic animals were randomly assigned to either a vehicle-
first (n = 7; Fig. 2, A) or CORT-first (n = 4; Fig. 5, A) regimen. In
the vehicle-first regimen, animals were monitored for 1–2 weeks to
determine baseline seizure frequency. After initial monitoring,
animals were treated with vehicle for 5–7 days (7 ml propylene
glycol/gram body weight 26/day s.c.), followed by a 1–2 week
recovery period and then 7 days of CORT treatment (3 mg/kg
CORT in propylene glycol vehicle 26/day s.c.). Two vehicle-first
animals did not complete the full 7-day CORT treatment; one
animal died after two days of treatment (Fig. 3, C) and one animal
was treated for only three days as part of an initial pilot (Fig. 3, D).
The CORT-first regimen was identical, except that the timing of
CORT and vehicle treatments was reversed in order to control for
the possibility that vehicle treatment and handling [71,72] might
alter later response to CORT. This also allowed us to control for
the progressive nature of epilepsy in animal models, in which
seizures become more frequent over time. CORT treatments were
designed to mimic endogenous CORT levels observed during
periods of chronic stress [73,74]. Each injection leads to elevated
CORT levels for less than 24 hours [75–77]. Throughout the
entire protocol, video-EEG data was monitored continuously to
ensure that no seizures would be missed.
Corticosterone measurements
Levels of CORT were determined in a subgroup of control mice
(n = 4) on the first days of vehicle and CORT treatment at three
timepoints: 1) three minutes prior to the injection (baseline), 2)
thirty minutes after vehicle or CORT injection and 3) two hours
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after after vehicle or CORT injection. Blood samples were
collected from the tail [29] in EDTA-coated tubes. Samples were
then centrifuged (3000 g, 15 min, 24uC) and plasma was isolated
and stored at 220uC until the time of use. Plasma corticosterone
levels were measured using a 125I radioimmunoassay (RIA) kit
(MP Biomedicals Inc., Solon, OH). All samples were run in
duplicate and in the same assay. Video-EEG was also recorded
from this group of animals. Injections of vehicle and CORT were
given between 8:30–9:30am in the morning and between 3:30–
4:30pm in the afternoon.
Statistical analysis
Statistical analyses were performed using SigmaPlot software
(version 12.3). Statistical comparisons to examine seizures and
epileptiform activity were made using a two-way ANOVA with
animal and treatment (vehicle or CORT injection) as factors.
Statistics were conducted on data normalized by rank transfor-
mation. A Holm-Sidak post-test was used to isolate significantly
different groups. Other statistical tests used are indicated in the
results. One-way ANOVA was run for seizure duration since not
all animals had seizures during all treatment periods, so the data
was disconnected and a two-way ANOVA was not possible.
Measures are expressed as means 6 SEM or medians (range) of
the raw (untransformed) data. P values #0.05 were accepted as
significant.
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